Trials / Conditions / Monoclonal Gammopathy of Renal Significance

Monoclonal Gammopathy of Renal Significance

4 registered clinical trials studyying Monoclonal Gammopathy of Renal Significance — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD NCT06418477	Peking University People's Hospital	Phase 2
Recruiting	A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gam NCT06083922	Memorial Sloan Kettering Cancer Center	Phase 2
Completed	MGRS: Clinical-histological Features of a Multicenter Case Series NCT05119309	University of Milano Bicocca	—
Unknown	Diagnosis of MGRS in Patients With Paraproteinemias: Clinical, Anatomopathological and Pathophysiological Stud NCT03629561	Academia Nacional de Medicina	—